pentobarbital has been researched along with Lymphoma, Non-Hodgkin in 1 studies
Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.
Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
White, RA | 1 |
Workman, P | 1 |
Owen, LN | 1 |
Bleehen, NM | 1 |
1 other study available for pentobarbital and Lymphoma, Non-Hodgkin
Article | Year |
---|---|
The penetration of misonidazole into spontaneous canine tumours.
Topics: Adenocarcinoma; Anesthesia, Intravenous; Animals; Carcinoma, Squamous Cell; Disease Models, Animal; | 1979 |